Bicycle Therapeutics plc (BCYC)
Automate Your Wheel Strategy on BCYC
With Tiblio's Option Bot, you can configure your own wheel strategy including BCYC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BCYC
- Rev/Share 0.3719
- Book/Share 10.6989
- PB 0.7907
- Debt/Equity 0.0112
- CurrentRatio 14.8567
- ROIC -0.2913
- MktCap 585451923.0
- FreeCF/Share -2.632
- PFCF -3.2145
- PE -2.88
- Debt/Assets 0.0094
- DivYield 0
- ROE -0.2511
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
Initiation | BCYC | RBC Capital Mkts | -- | Outperform | -- | $35 | Sept. 6, 2024 |
News
Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the poster presentation of two abstracts at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in Chicago. Poster Presentation Details: Title: Phase 1/2 Duravelo-1 study: Preliminary results of Nectin.
Read More
Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted
Published: April 22, 2025 by: Seeking Alpha
Sentiment: Neutral
Bicycle Therapeutics focuses on novel conjugated targeted therapies for cancer, with promising early results but no clear evidence of superior efficacy yet. Their lead compound, zelenectide pevedotin, shows potential in urothelial carcinoma with a 45% response rate, but more robust studies are needed. Financially, BCYC is well-capitalized with $879.5 million in cash, providing a runway into 2027 despite high operating expenses.
Read More
About Bicycle Therapeutics plc (BCYC)
- IPO Date 2019-05-23
- Website https://www.bicycletherapeutics.com
- Industry Biotechnology
- CEO Dr. Kevin Lee M.B.A., Ph.D.
- Employees 305